Constitutive activation of signal transducer and activator of transcription (STAT) proteins has been detected in a wide variety of human primary tumor specimens and tumor cell lines including blood malignancies, head and neck cancer, and breast cancer. We have previously demonstrated a high frequency of Stat3 DNA-binding activity that is constitutively-induced by an unknown mechanism in human breast cancer cell lines possessing elevated EGF receptor (EGF-R) and c-Src kinase activities. Using tyrosine kinase selective inhibitors, we show here that Src and JAK family tyrosine kinases cooperate to mediate constitutive Stat3 activation in the absence of EGF stimulation in model human breast cancer cell lines. Inhibition of Src or JAKs results in dose-dependent suppression of Stat3 DNA-binding activity, which is accompanied by growth inhibition and induction of programmed cell death. In addition, transfection of a dominant-negative form of Stat3 leads to growth inhibition involving apoptosis of breast cancer cells. These results indicate that the biological eects of the Src and JAK tyrosine kinase inhibitors are at least partially mediated by blocking Stat3 signaling. While EGF-R kinase activity is not required for constitutive Stat3 activation in breast cancer cells, EGF stimulation further increases STAT DNA-binding activity, consistent with an important role for EGF-R in STAT signaling and malignant progression. Analysis of primary breast tumor specimens from patients with advanced disease revealed that the majority exhibit elevated STAT DNA-binding activity compared to adjacent non-tumor tissues. Our ®ndings, taken together, suggest that tyrosine kinases transduce signals through Stat3 protein that contribute to the growth and survival of human breast cancer cells in culture and potentially in vivo.
Constitutive activation of signal transducer and activator of transcription (STAT) proteins has been detected in a wide variety of human primary tumor specimens and tumor cell lines including blood malignancies, head and neck cancer, and breast cancer. We have previously demonstrated a high frequency of Stat3 DNA-binding activity that is constitutively-induced by an unknown mechanism in human breast cancer cell lines possessing elevated EGF receptor (EGF-R) and c-Src kinase activities. Using tyrosine kinase selective inhibitors, we show here that Src and JAK family tyrosine kinases cooperate to mediate constitutive Stat3 activation in the absence of EGF stimulation in model human breast cancer cell lines. Inhibition of Src or JAKs results in dose-dependent suppression of Stat3 DNA-binding activity, which is accompanied by growth inhibition and induction of programmed cell death. In addition, transfection of a dominant-negative form of Stat3 leads to growth inhibition involving apoptosis of breast cancer cells. These results indicate that the biological eects of the Src and JAK tyrosine kinase inhibitors are at least partially mediated by blocking Stat3 signaling. While EGF-R kinase activity is not required for constitutive Stat3 activation in breast cancer cells, EGF stimulation further increases STAT DNA-binding activity, consistent with an important role for EGF-R in STAT signaling and malignant progression. Analysis of primary breast tumor specimens from patients with advanced disease revealed that the majority exhibit elevated STAT DNA-binding activity compared to adjacent non-tumor tissues. Our ®ndings, taken together,
Introduction
Signal transducers and activators of transcription (STATs) are a family of cytoplasmic proteins that, upon ligand-induced activation of cytokine receptors, directly relay receptor-generated signals into the nucleus (Bromberg and Darnell, 2000; Decker and Kovarik, 1999; Ihle et al., 1998; Schindler and Brutsaert, 1999) . Ligand-induced tyrosine phosphorylation of cytokine receptors by receptor-associated Janus kinases (JAKs) creates receptor docking sites for recruitment of cytoplasmic STAT proteins (Yeh and Pellegrini, 1999) . Upon association with phophorylated receptors, STATs are activated by phosphorylation on carboxy-terminal tyrosine residues and form homo-or hetero-dimers via reciprocal SH2 domain-phosphotyrosine interactions. Activated STAT dimers rapidly translocate into the nucleus, bind to recognition sequences in the promoters of speci®c cellular genes, and regulate their transcription (Darnell, 1997; Decker and Kovarik, 1999) . In addition to cytokines, several growth factors, such as epidermal growth factor (EGF) and platelet-derived growth factor (PDGF), also induce transient activation of signaling through STATs (David et al., 1996; Leaman et al., 1996; Ru-Jamison et al., 1993; Vignais et al., 1996; Zhong et al., 1994) . Recent studies have demonstrated essential functions for STAT proteins in signaling pathways critical to normal cellular processes including immune function, development, dierentiation, proliferation and survival (Akira, 1999 (Akira, , 2000 Dearolf, 1999; Hirano et al., 2000; Levy, 1999; Mui, 1999; Smithgall et al., 2000) .
Constitutive activation of STAT proteins has been detected within the context of malignant cellular transformation (Bowman et al., 2000; Catlett-Falcone et al., 1999a; Garcia and Jove, 1998) . Previous studies have shown that constitutive activation of one STAT family member, Stat3, is associated with transformation by v-Src and other viral oncoproteins that activate tyrosine kinase signaling pathways (Cao et al., 1996; Chaturvedi et al., 1997; Garcia et al., 1997; Yu et al., 1995) . More recent studies have demonstrated that Stat3-mediated transcription of cellular genes is required for v-Src-induced cellular transformation (Bromberg et al., 1998; Turkson et al., 1998) . Constitutive activation of STATs has also been detected in cells transformed by other oncoproteins with tyrosine kinase activity, such as v-Abl, v-Fps, vEyk, v-Ros and BCR-Abl Carlesso et al., 1996; Danial and Rothman, 2000; de Groot et al., 1999; Frank and Varticovski, 1996; Ilaria and Van Etten, 1996; Nelson et al., 1998; Shuai et al., 1996; Zong et al., 1998) . In addition, constitutive STAT activation occurs frequently in a variety of human tumor cell lines and primary human tumors including leukemias, lymphomas, multiple myeloma, prostate cancer, head and neck cancer, and breast cancer (Bowman et al., 2000; Coer et al., 2000; Fernandes et al., 1999; Garcia et al., 1997; Lin et al., 2000; Sartor et al., 1997; Song and Grandis, 2000; Watson and Miller, 1995; Zuyao et al., 2000) . Moreover, constitutively-activated STAT mutants have been shown to alter cellular growth control and directly induce cellular transformation (Ariyoshi et al., 2000; Bromberg et al., 1999; Bromberg and Darnell, 2000; Demoulin et al., 2000) . These ®ndings suggest that constitutive activation of STAT proteins may have critical roles in the progression of human cancers that frequently acquire aberrant expression and/or activation of tyrosine kinase signaling pathways.
Activation of signaling pathways involving the EGF receptor (EGF-R) family tyrosine kinases occurs frequently during progression of human breast cancer (Cance and Liu, 1995; Cohen et al., 1998; Kim and Muller, 1999; Ma et al., 1998; Rajkumar and Gullick, 1994) . Often, activation of signaling through these receptor tyrosine kinases is associated with aberrant overexpression of receptor ligands (Gullick and Srinivasan, 1998) . Activation of the non-receptor tyrosine kinase, c-Src, has also been detected in breast cancer cell lines and primary breast tumor specimens Luttrell et al., 1994; Muthuswamy and Muller, 1994; Ottenho-Kal et al., 1992) . Current evidence suggests that activation of signaling through these tyrosine kinase pathways is critical to malignant transformation of mammary epithelial cells and progression of human breast cancer Muthuswamy and Muller, 1994; Sheeld, 1998) . Because signaling by STAT proteins is associated with activation of the EGF-R and Src tyrosine kinases (Cao et al., 1996; Chaturvedi et al., 1998; David et al., 1996; Leaman et al., 1996; Reddy et al., 2000; Ru-Jamison et al., 1993; Yu et al., 1995; Zhong et al., 1994) , we examined STAT DNA-binding activity in nuclear extracts from human breast cancer cell lines exhibiting overexpression and/or activation of these proteins. We previously reported a high frequency of constitutive Stat3 activation in a panel of human breast cancer cell lines possessing elevated levels of EGF-R and c-Src activity (Garcia et al., 1997) . In the present study, we used pharmacologic inhibitors selective for EGF-R, Src and JAK family kinases to examine the role of these tyrosine kinases in constitutive and EGF-stimulated Stat3 activation in human breast cancer cell lines. In addition, we used a dominant-negative form of the Stat3 protein to investigate the contribution of activated Stat3 signaling to transformation of breast cancer cells. Our results indicate that activated Stat3 transduces signals downstream of tyrosine kinases that regulate growth and survival of human breast cancer cells, and suggest that inhibitors of tyrosine kinases that block Stat3 signaling represent potential novel therapeutics for breast cancer.
Results

Analysis of STAT DNA-binding activity in human breast cancer cell lines
We have previously reported that constitutive activation of Stat3 DNA-binding activity occurs in ®ve of nine human breast cancer cell lines but not in mammary epithelial cell lines established from nonmalignant tissue (Garcia et al., 1997) . To further characterize the frequency of Stat3 activation in human breast cancer cells, we examined STAT DNA-binding activity in a second panel of human breast cancer cell lines by electrophoretic mobility shift assay (EMSA). As shown in Figure 1a , constitutive Stat3 DNAbinding activity is present, to dierent extents, in nuclear extracts from seven of the 11 human breast cancer cell lines examined. The radiolabeled probe corresponds to a high-anity variant of the c-fos sisinducible element (hSIE), which binds Stat1 and Stat3 dimers (Wagner et al., 1990; Yu et al., 1995) . While in most cases Stat3 was the predominant activated STAT protein detected, the pattern of EMSA complexes detected using nuclear extracts from Hs578T cells was consistent with activation of both Stat1 and Stat3 (Figure 1a, lane 9) . By contrast, Hs578Bst cells, a nonmalignant counterpart of Hs578T, does not possess detectable STAT DNA-binding activity (Garcia et al., 1997) . Figure 1b, shows results of supershift analysis using antibodies against speci®c STAT family members and nuclear extracts from MDA-MB-435s and GI-101A cells. This analysis demonstrates that Stat3 is the predominant STAT protein activated in human breast cancer cell lines in the absence of EGF stimulation.
Roles of Src, EGF-R and JAKs in STAT activation in 10T1/2 mouse fibroblasts
Because constitutive activation of Stat3 occurs in human breast cancer cell lines possessing activated EGF-R and Src kinases, we utilized 10T1/2 murine ®broblasts overexpressing wild-type EGF-R and/or cSrc to further characterize the regulation of STAT proteins by these tyrosine kinases (Luttrell et al., 1988; Maa et al., 1995; Parsons and Parsons, 1997; Wilson et al., 1989; Wilson and Parsons, 1990) . As shown in Figure 2a , overexpression of wildtype c-Src by itself does not signi®cantly alter Stat3 DNA-binding activity in these cells (lane 2). Overexpression of wild-type EGF-R alone in these cells results in slightly elevated Stat3 DNA-binding activity (lane 4). In contrast, overexpression of both wild-type c-Src and EGF-R kinases in 10T1/2 cells results in cooperative activation of Stat3 DNA-binding activity (lane 3). Interestingly, under the unstimulated conditions examined here, only activation of Stat3 was observed in 10T1/2 cells overexpressing both c-Src and EGF-R proteins. These results are very similar to the pattern of activated STAT proteins detected in nuclear extracts from human breast cancer cell lines possessing elevated expression/activation of EGF-R and Src kinases under basal, unstimulated conditions ( Figure  1 ) (Garcia et al., 1997) . The synergistic activation of Stat3 by co-expressed c-Src and EGF-R correlates well with the cooperative increase in mitogenic responsiveness to EGF and the potentiation of oncogenic properties observed in 10T1/2 cells co-expressing both kinases (Luttrell et al., 1988; Maa et al., 1995; Parsons and Parsons, 1997; Tice et al., 1999; Wilson et al., 1989; Wilson and Parsons, 1990) , suggesting that Stat3 activation may function in transduction of oncogenic signaling downstream of these tyrosine kinases.
The regulation of STAT proteins by EGF-R and Src kinases was further investigated following EGF stimulation in 10T1/2 transfectants pretreated with EGF-R (Fry, 1999) , Src or JAK (Levitzki, 1999) 8) . In contrast to basal activation of STATs, EGF-stimulated STAT activation in these cells was speci®cally inhibited by pretreatment with the EGF-R selective inhibitor, PD158780 (lane 6), as expected.
As shown in Figure 2d , the basal constitutive activation of Stat3 in 10T1/2 cells overexpressing both c-Src and EGF-R kinases was speci®cally inhibited by pretreatment with the Src-selective inhibitor, PD180970 (lane 3). These ®ndings contrast with the slight increase in Stat3 DNA-binding activity observed in 10T cells overexpressing c-Src alone or EGF-R alone after treatment with PD180970 in the absence of EGF stimulation (Figure 2b,c, lane 3 ). These results demonstrate that the cooperative activation of Stat3 by Src and EGF-R kinases under basal, unstimulated conditions requires Src kinase activity but not EGF-R kinase activity. By contrast, EGF-stimulated activation of STATs in 10T1/2 cells overexpressing both c-Src and EGF-R was speci®cally inhibited by pretreatment with PD158780 (lane 6), demonstrating that EGFstimulated activation of STATs in these cells requires EGF-R kinase activity but not Src kinase activity. Treatment with the JAK-selective inhibitor AG490 did not have any eect on the basal or EGF-stimulated The eects of treatment with PD158780, PD180970 or AG490 on Src activation in intact cells were examined by Western blotting using an antibody that recognizes the active form (autophosphorylated on tyrosine 419 in human c-Src/tyrosine 416 in chicken c-Src) of the protein (Laudano and Buchanan, 1986) . Figure 6 shows that treatment of MDA-MB-468 cells with the highest dose of EGF-R inhibitor PD158780 had no eect on autophosphorylation of Src (lane 2). As expected, autophosphorylation of c-Src in MDA-MB-468 cells was eciently inhibited at all concentrations of PD180970 examined (lanes 3 ± 5). By contrast, treatment of MDA-MB-468 cells with increasing concentrations of the JAK inhibitor AG490 did not result in signi®cant inhibition of Src autophosphorylation (lanes 6 ± 8). Because AG490 induced growth inhibition of MDA-MB-468 cells (Figure 4 ) at concentrations that do not inhibit Src activity, these results demonstrate that the inhibitory properties of AG490 are not mediated through inactivation of Src. Consistent with these ®ndings, we have observed kinase-selective inhibitory activity of these compounds on PDGF-induced activation of STATs in Balb/c-3T3 ®broblasts (Wang et al., 2000) as well as in immunecomplex kinase assays of v-Src and Jak1 proteins immunoprecipitated from v-Src transformed NIH 3T3 ®broblasts (Zhang et al., 2000) . Previous studies have also demonstrated speci®city of action of these compounds towards puri®ed tyrosine kinases (Fry, 1999; Kraker et al., 2000; Levitzki, 1999) . Our ®ndings are consistent with a requirement for both Src and JAK tyrosine kinases for the basal constitutive activation of Stat3 in MDA-MB-468 cells, and suggest that activated Stat3 is a critical mediator of growth regulatory signaling downstream of these kinases in human breast cancer cells. (Moasser et al., 1999) . Treatment of MDA-MB-468 cells with AG490 had less dramatic eects on cell cycle distribution, resulting in a slight reduction in the number of cells in the G1 phase of the cell cycle, with minimal eects on G2/M distribution and a delayed accumulation of cells in S phase. These results suggest divergent functions for Src and JAKs in regulation of cell cycle progression in human breast cancer cells. In addition, the results demonstrate that Stat3 inactivation and growth inhibition of MDA-MB-468 cells by PD180970 and AG490 is associated with perturbations in cell cycle progression.
PD180970 and AG490 induce apoptosis of MDA-MB-468 breast cancer cells
The eects of PD180970 and AG490 on survival of MDA-MB-468 cells were examined using cell surface binding of¯uorescent antibody to Annexin V as an early indicator of programmed cell death. As shown in Figure 8a , growth inhibition of MDA-MB-468 cells in response to treatment with PD180970 or AG490 for 48 h was accompanied by dramatic changes in cell Figure 6 Dierential eects of PD158780, PD180970, and AG490 on Src activation in MDA-MB-468 human breast cancer cells. MDA-MB-468 cells were treated with 500 nM PD158780 and increasing concentrations of PD180970 or AG490 for 24 h prior to lysis. Total Src protein was immunoprecipitated from lysates containing normalized amounts of cellular protein and resolved by SDS ± PAGE. Immunoprecipitated Src was transferred to nitrocellulose and the membrane was probed using antiPTyr416/419Src monoclonal antibody followed by incubation with HRP-conjugated goat anti-mouse Kappa chain. Levels of tyrosine 419 phosphorylated human Src protein were visualized using ECL Western blotting detection reagents on the survival of MDA-MB-468 cells, we measured the eect of Stat3b, a dominant-negative regulator of Stat3-dependent signaling Catlett-Falcone et al., 1999b; Turkson et al., 1998) , on survival of these cells. Figure 9 shows results of a representative experiment in which cell surface binding of Annexin V was measured by¯ow cytometry 48 h after transfection of MDA-MB-468 cells with a bicistronic pIRES vector expressing enhanced green uorescence protein (EGFP) with or without coexpression of Stat3b. As shown in Figure 9b , cells coexpressing EGFP and Stat3b possess approximately twofold higher cell surface Annexin V binding compared to cells expressing only EGFP (shown in Figure 9a ). These results demonstrate that directly blocking Stat3 signaling induces apoptosis of human breast cancer cells. Furthermore, because inactivation of Stat3-dependent signaling with Stat3b mimics the eects of Src and JAK selective pharmacologic inhibitors, our ®ndings provide further evidence for an important role of activated Stat3 as a transducer of survival signals downstream of the Src and JAK tyrosine kinases in human breast cancer cells.
Activation of STATs in human primary tumors
To determine if activation of STAT proteins is associated with progression of breast cancer in vivo, we performed EMSA analysis using nuclear extracts prepared from a series of primary human tissue specimens (Figure 10 ). Because STAT DNA-binding activity could be potentially diminished by phosphatases and/or proteases acting on STATs between the time of surgical excision and freezing of tumor specimens, we ®rst determined whether the STAT pro®le is preserved in specimens that were rapidly processed. Panel A shows that specimens snap frozen in liquid nitrogen within 15 min of surgical excision retain the levels of STAT activation present at the time of excision in tumor (T) and adjacent non-tumor (A) tissues. Figure 10 shows results of EMSA analysis using nuclear extracts prepared from nine independent non-malignant primary tissue specimens (in¯ammatory breast disease, benign ®broadenomas, and ®brocystic disease) as well as ®ve independent primary breast tumor specimens (in®ltrating ductal or lobular carcinoma). Little or no detectable STAT DNA-binding activity was present in nuclear extracts from all of the non-malignant primary tissue specimens examined (lanes N1 through N9). By contrast, elevated STAT DNA-binding activity was detected, to dierent extents, in the majority of unmatched primary tumor specimens examined (lanes T1 through T5). To further characterize the association between activation of STATs and breast cancer progression, we evaluated STAT DNA-binding activity in nuclear extracts prepared from matched primary tissue specimens. Figure 10c shows that elevated STAT DNA-binding activity was present in at least ®ve of seven tumors (in®ltrating ductal or lobular carcinoma) compared to adjacent non-tumor tissues. To date, we have detected increased STAT DNA-binding activity in breast tumor specimens from 18 of 23 (78%) sets of matched primary tissue specimens (data not shown). More extensive analysis of STAT activity in a large number of tumor specimens from patients with advanced breast cancer is currently in progress.
Supershift analysis with antibodies to speci®c STAT proteins revealed activation of both Stat1 and Stat3 in the majority of tumor specimens examined (Figure 10d , and data not shown). These ®ndings contrast with the nearly exclusive activation of Stat3 observed in human breast cancer cell lines in the absence of EGF stimulation (Figure 1) . Interestingly, the EMSA pattern observed in tumor specimens is similar to that observed in response to EGF stimulation, where dimers involving both Stat1 and Stat3 are induced (e.g., Figures 2 and 3) . Therefore, the EMSA pattern detected in primary breast tumor specimens may re¯ect autocrine or paracrine signaling by cytokines and growth factors, including EGF, present in the mammary gland microenvironment that may activate signaling through STATs and potentially contribute to oncogenic signaling and progression. Our results demonstrate that activation of STAT proteins is associated with primary breast tumors in vivo, consistent with a role for STAT activation in breast cancer progression.
Discussion
We previously reported that constitutive activation of Stat3 occurs in ®broblasts transformed by oncoproteins that activate tyrosine kinase signaling pathways and in human breast cancer cell lines (Yu et al., 1995; Garcia et al., 1997; Sartor et al., 1997) . In this study, we further investigated the signaling pathways that mediate constitutive Stat3 activation and the function of these pathways in growth control of model breast carcinoma cells. EMSA analysis using nuclear extracts from a panel of additional human breast cancer cell lines revealed constitutive activation of STAT DNAbinding activity, predominantly Stat3, in the majority of cell lines examined in the absence of EGF stimulation (Figure 1 ). Because constitutive activation of Stat3 occurs in breast cancer cell lines possessing overexpressed/activated EGF-R and c-Src kinases (Garcia et al., 1997; Sartor et al., 1997) , we examined regulation of STATs in mouse 10T1/2 ®broblasts overexpressing wild-type c-Src and/or EGF-R tyrosine kinases. Signi®cantly, we observed a cooperative activation of constitutive Stat3 DNA-binding activity in 10T1/2 cells co-expressing wild-type c-Src and EGF-R (Figure 2 ) that correlates with cooperative oncogenic signaling by the kinases in these cells (Luttrell et al., 1988; Maa et al., 1995; Parsons and Parsons, 1997; Tice et al., 1999; Wilson et al., 1989; Wilson and Parsons, 1990) . Using tyrosine kinase selective inhibitors, the cooperative activation of Stat3 by coexpressed Src and EGF-R was shown to require Src kinase activity but not EGF-R kinase activity. Conversely, EGF-stimulated STAT activation in these cells required EGF-R kinase activity but not c-Src kinase activity (Figure 2 ). These results demonstrate a fundamental mechanistic dierence between unstimulated and EGF-stimulated regulation of STATs by the Src and EGF-R kinases. In addition, the results in (Figure 6 ), demonstrating that AG490-induced growth inhibition occurs through a Src-independent mechanism. Thus, in all cases, inhibition of Src and JAK tyrosine kinase activity that blocks Stat3 signaling correlates with growth inhibition. Conversely, inhibition of Src and JAK tyrosine kinase activity in cells that lack constitutive Stat3 activation has no eect on cell growth. These results provide additional evidence that, in addition to Src, the JAK family kinases have important functions in regulation of STAT DNAbinding activity and growth of human breast cancer cells. Our ®ndings, taken together, demonstrate an association between constitutive Stat3 activation and Src/JAK-induced growth regulation, and suggest that activated Stat3 is a critical downstream eector of Src/ Previous studies using the Src selective inhibitor PD173955, a compound structurally related to PD180970, demonstrated that inhibition of Src in MDA-MB-468 cells was associated with mitotic arrest (Moasser et al., 1999) . Consistent with these ®ndings, we also observed cell cycle perturbations in MDA-MB-468 cells in response to treatment with the Src selective inhibitor PD180970 (Figure 7) . In addition, treatment of MDA-MB-468 cells with PD180970 and AG490 induced dramatic programmed cell death (Figure 8 ). These ®ndings indicate that activated Stat3 is critical to signaling downstream of Src and JAK kinases involved in regulation of growth and survival of human breast cancer cells. However, we cannot exclude the possibility that the Src and JAK selective inhibitors block other signaling pathways that may regulate the growth and survival of these cells. Transfection of MDA-MB-468 cells with Stat3b, a dominant-negative regulator of Stat3 signaling, induced programmed cell death to a level similar to that observed in cells treated with PD180970 and AG490, suggesting that at least part of the biological eects of these tyrosine kinase inhibitors are mediated through blocking Stat3 signaling. These ®ndings are consistent with earlier studies showing that activated Stat3 signaling contributes to the growth and survival of human myeloma cells (Catlett-Falcone et al., 1999b) .
It has been previously reported that EGF and heregulin-induced activation of STATs in A431 cells requires functional Src kinase but not functional JAK kinases (Olayioye et al., 1999) . In this study, we observe a requirement for Src activity in EGF-R mediated activation of STATs in 10T1/2 ®broblasts and MDA-MB-468 breast cancer cells, but only under unstimulated conditions (Figures 2 and 3) . In both cell lines, we observe a switch from basal constitutive activation of Stat3, which requires Src kinase activity, to an EGF-stimulated activation of Stat1 and Stat3, which requires EGF-R kinase activity but not Src. By contrast, we observe a requirement for JAK kinases in unstimulated and EGF-stimulated regulation of STATs that is cell-type speci®c (Figures 2 and 3) . Other studies have shown that Src and JAK family kinases cooperate with cytokine/growth factor receptors in normal as well as oncogenic signaling (Chaturvedi et al., 1998; Reddy et al., 2000; Wang et al., 2000; Zhang et al., 2000) . It has been proposed that these kinases act in concert in a model whereby JAKs phosphorylate docking sites on a receptor for recruitment of STATs, which in turn are phosphorylated by receptor-associated JAK or Src kinases (Reddy et al., 2000; Zhang et al., 2000) . This model does not exclude a direct role for receptor A preliminary analysis of STAT DNA-binding activity in nuclear extracts prepared from primary breast tumor specimens and matched adjacent nonmalignant tissues showed increased STAT DNAbinding activity, predominantly Stat3, in a majority of breast carcinoma specimens examined (Figure 10 and our unpublished results). To a lesser extent, Stat1 activation is also detected in primary breast tumor specimens, as observed in model breast cancer cell lines stimulated with EGF. Furthermore, other studies suggest an important role for cooperativity between Src and EGF-R in EGF-induced Stat5 activation that contributes to oncogenic signaling by these kinases in breast cancer (Kloth et al., 2001) . Thus, while Src and JAK family kinases are required for the basal constitutive Stat3 activation in breast cancer cells, EGF induces Stat5 activation in these cells, consistent with Stat3 and Stat5 being the STAT family members most strongly associated with oncogenesis (Bowman et al., 2000) . These ®ndings indicate that, in addition to the potential contribution of Src and JAK family kinases revealed by the studies in model human cell lines, EGF-like ligands and/or cytokines present in the mammary gland microenvironment may contribute to elevated and sustained activation of signaling through STATs in primary breast tumors. Although more extensive analysis of the ligands and tyrosine kinases that mediate STAT activation during breast tumor progression will be necessary, our preliminary ®ndings provide evidence that activation of speci®c STAT proteins is associated with malignant transformation of mammary epithelial cells.
Based on our ®ndings, a model is proposed for Stat3 function in growth regulatory signaling in human breast cancer cells (Figure 11 ). In this model, the constitutive activation of STATs, including Stat3, transduces oncogenic signaling downstream of Src and JAK tyrosine kinases that is critical to growth and survival of human breast cancer cells. While EGF-R may cooperate with Src in the absence of EGF stimulation, this cooperation does not require EGF-R kinase activity. Additional increases in levels of STAT signaling may be stimulated by EGF-related ligands that activate EGF-R family receptor tyrosine kinases, or by other growth factors and cytokines that act through distinct receptors, and thereby participate in malignant progression in vivo. In the presence of EGF, the mechanism of activation of STATs switches from a dependence on Src/JAK kinase activities to a dependence on EGF-R/JAK kinase activities in breast cancer cells. Thus, growth factor receptors, cytokine receptors and non-receptor tyrosine kinases may cooperate for maximal STAT activation within the tumor microenvironment. Our ®ndings reported here suggest that blocking tyrosine kinase signaling pathways that mediate Stat3 activation may be eective in blocking malignant progression of breast cancer. This possibility is further supported by the observation that gene therapy with dominant-negative Stat3 suppresses the in vivo growth of melanoma tumors in a mouse model (Niu et al., 1999) . Among the genes regulated by Stat3 that potentially control growth and survival of tumor cells are bcl-x, mcl-1, cyclin D1, and c-myc (Bowman et al., 2000; Bromberg and Darnell, 2000) . Ongoing studies are directed at evaluating the anti-tumor ecacy of Src and JAK selective inhibitors in mouse models of human breast cancer and further de®ning the Stat3-regulated target genes that may contribute to malignant progression.
Materials and methods
Cell lines and cell culture
MDA-MB-468 and SK-BR-3 human breast cancer cells were grown as previously described (Garcia et al., 1997) . 10T1/2 cells transfected with wild-type Src and/or EGF-R tyrosine kinases were cultured as described earlier (Luttrell et al., 1988; Maa et al., 1995; Tice et al., 1999; Wilson et al., 1989) . The human breast carcinoma cell lines Hs578T, MDA-MB435s and DU 4475 were kindly provided by Dr Donald Fujita (University of Calgary Medical Center) (Egan et al., 1999) . Hs578T and MDA-MB-435s cells were grown in DMEM medium supplemented with 10% fetal bovine serum (FBS). DU 4475 cells were grown in RPMI medium supplemented with 10% FBS. The MCF-7, T-47D, MDA-MB-231, MDA-MB-361, and MDA-MB-453 human breast cancer cell lines were generously provided by Dr Neal Rosen (Memorial Sloan-Kettering Cancer Center) (Moasser et al., 1999) . The cell lines were grown in DME/F12 media (1 : 1) supplemented with 10% FBS. GI-101A cells were a kind gift from Dr Alex Aller (Goodwin Institute for Cancer Research) (Morrissey and Raney, 1998) and grown in RPMI media supplemented with 25 mg/ml amphotericin B, 2 mM glutamine and 20% FBS.
Treatment of human breast cancer cell lines with tyrosine kinase selective inhibitors and EGF
For treatment with PD158780 (Fry, 1999) , PD180970 and AG490 (Levitzki, 1999) , stock solutions of the compounds in 100% DMSO were diluted directly into the media to indicated concentrations followed by incubation at 378C. For time-course and dose-response experiments, media plus inhibitors were changed every 24 h with re-dosing of inhibitors every 12 h. For experiments involving treatment with EGF, dishes were placed on ice and 100 mg/ml EGF stock solution (Gibco BRL) was diluted directly into media to 10 nM ®nal concentration. Dishes were incubated at 378C for 10 min prior to lysis and/or preparation of nuclear extracts. Cell numbers were determined by counting with a hemocytometer using trypan blue dye exclusion.
Cell lysis and Western blot analysis
Human breast cancer cells treated with PD158780, PD180970 or AG490 were lysed in NP-40 lysis buer (20 mM Tris, pH 7.4, 1.0% NP-40, 140 mM NaCl, 20 mM NaF, 1 mM Na 3 VO 4 , 1 mM Na 4 P 2 O 7 , 0.1 mM aprotinin, 1 mM leupeptin, 1 mM antipain) on ice. After centrifugation at 13 000 r.p.m.
for 1 h at 48C, protein concentration was determined for clari®ed lysates. Src protein was immunoprecipitated from lysate volumes containing normalized total cellular protein using Mab 327 (v-src Ab-1; Oncogene Research) and immobilized protein G (Pierce). Immune complexes were washed, resuspended in SDS sample buer and immunoprecipitated proteins were resolved by SDS ± PAGE. Proteins were transferred to nitrocellulose membrane using a semi-dry transfer apparatus and membranes were probed with antiPtyr416/419Src Mab (Laudano and Buchanan, 1986) in PBS containing 0.05% Tween 20 and 10% non-fat dry milk, followed by incubation with HRP-conjugated goat antimouse kappa chain (Southern Biotechnology Associates). Proteins were visualized using ECL Western blotting detection reagents (Amersham).
Transfections
All transfections were carried out in 6-well plates. Cells were transfected with either the vector encoding only enhanced green¯uorescence protein (EGFP), pIRES-EGFP, or the same vector encoding both EGFP and dominant-negative Stat3b, pIRES-Stat3b, which have been previously described (Catlett-Falcone et al., 1999b) . 3610 5 cells were plated per well, and plasmid DNAs (3 mg) were mixed with Geneporter reagent (Gene Therapy Systems) in serum free media and incubated at room temperature for 30 min. The DNAGeneporter mix was added to cell monolayers for 5 h, after which monolayers were washed and fresh media containing 20% FBS was added to the cells followed by incubation at 378C. For Annexin V binding studies, cells were harvested at 48 h post-transfection, washed and analysed by¯ow cytometry as described below.
Procurement of primary human tissue specimens
Primary human tissue specimens were obtained through the Mott Cancer Center Tumor Bank using IRB approved procedures. Following diagnostic examination, tissue specimens were frozen in liquid nitrogen within 15 ± 20 min after surgical removal to ensure preservation of the STAT DNAbinding activities. To con®rm that analysis of STAT activity was performed on the appropriate tumor or non-tumor tissues, mirror images of the tissue specimens were used for preparation of frozen sections for pathologic evaluation and tissue banking by the Tumor Bank. Tissue specimens were ground to powder consistency in liquid nitrogen using a mortar and pestle, and stored in liquid nitrogen for nuclear extract preparation as described below.
Nuclear extract preparation and electrophoretic mobility shift assays (EMSA)
STAT DNA-binding assays were performed as described previously (Garcia et al., 1997; Yu et al., 1995) . Brie¯y, nuclear extracts were prepared from cultered cells in hypertonic buer (20 mM HEPES, pH 7.9, 420 mM NaCl, 1 mM EDTA, 1 mM EGTA, 20% glycerol, 20 mM NaF, 1 mM Na 3 VO 4 , 1 mM Na 4 P 2 O 7 , 1 mM DTT, 0.5 mM PMSF, 0.1 mM aprotinin, 1 mM leupeptin, 1 mM antipain). For preparation of nuclear extracts from primary tissue specimens, ground tissue powder was placed in 1 ml tubes and nuclear extracts were prepared in hypertonic buer containing 60 mM NaF, 3 mM Na 3 VO 4 , 3 mM Na 4 P 2 O 7 , 3 mM DTT, 1.5 mM PMSF, 0.3 mM aprotinin, 3 mM leupeptin, and 3 mM antipain. Normalized extracts containing 3 ± 8 mg of total protein were incubated with a double-stranded 32 P-radiolabeled hSIE oligonucleotide probe as described previously (Garcia et al., 1997; Yu et al., 1995) . Protein-DNA complexes were resolved by non-denaturing polyacrylamide gel electrophoresis (PAGE) and detected by autoradiography.
Anti-Stat1, Stat3 and Stat5 polyclonal antibodies used to identify speci®c STAT family members by EMSA were obtained from Santa Cruz Biotechnologies. For use in supershift assays, 1 ml volumes of the STAT antibodies were incubated with nuclear extracts for 20 min at room temperature prior to addition of radiolabeled probe(s) and electrophoresis. Protein-DNA complexes were detected as described above.
Cell cycle analysis
For cell cycle analysis following treatment with PD158780, PD180970 or AG490, cells were incubated in 30 mg/ml BrdU at 378C for 30 min prior to harvesting of cells. Cells were trypsinized, washed with cold PBS followed by ®xation with ethanol at 48C. Fixed cells were digested with 0.04% pepsin in 0.1% HCl for 1 h at 378C, followed by incubation in 2 N HCl for 30 min and treatment with 0.1 M sodium borate. Samples were incubated with FITC-conjugated anti-BrdU antibody (Becton Dickinson) at room temperaure for 60 min in the dark, followed by incubation in the dark for 30 min in buer containing 10 mg/ml propidium iodide (PI) and 500 mg/ ml RNase A. 1610 6 cells per experimental condition were used for processing and analysis of¯uorescence on a BectonDickinson FACScan using Cell Quest software. Percentages of cells of G1 and G2/M were determined by PI staining, while the fraction of cells in S was determined by BrdU incorporation.
Annexin V binding assays
Following treatment with PD158780, PD180970 or AG490, or transfection with pIRES vectors, cells were detached by trypsinization, counted and pelleted (1000 r.p.m. for 5 min). Cell pellets were washed once with PBS (pH 7.4) and once in Annexin V binding buer (10 mM HEPES, pH 7.4, 140 mM NaCl, 2.5 mM CaCl 2 ). 1610 5 cells were transferred to a 12675 mm tube and 5 ml of Annexin V-PE was added per tube and allowed to incubate at room temperature for 15 min in the dark. 1610 4 cells per experimental condition were analysed for¯uorescence on a Becton-Dickinson FACScan using Cell Quest software.
